About TELO2-interacting protein 1 homolog
TELO2-interacting protein 1 homolog (TTI1) is a protein
from Homo sapiens identified by UniProt accession
O43156, 1089 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | TELO2-interacting protein 1 homolog |
|---|
| UniProt accession | O43156 |
|---|
| Gene | TTI1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1089 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (26)
Diseases linked to this target (Open Targets).
- Intellectual disability, severe · score 0.41
- Abnormal brain morphology · score 0.27
- neurodegenerative disease · score 0.25
- genetic disorder · score 0.19
- non-small cell lung carcinoma · score 0.07
- cholesterol-ester transfer protein deficiency · score 0.04
- hypertriglyceridemia 2 · score 0.04
- neoplasm · score 0.03
- pancreatic triacylglycerol lipase deficiency · score 0.03
- pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43156-F1 | alphafold | PREDICTED | 81.27 | — |
Amino-acid sequence (1089 residues)
MAVFDTPEEA FGVLRPVCVQ LTKTQTVENV EHLQTRLQAV SDSALQELQQ YILFPLRFTL KTPGPKRERL IQSVVECLTF VLSSTCVKEQ ELLQELFSEL SACLYSPSSQ KPAAVSEELK LAVIQGLSTL MHSAYGDIIL TFYEPSILPR LGFAVSLLLG LAEQEKSKQI KIAALKCLQV LLLQCDCQDH PRSLDELEQK QLGDLFASFL PGISTALTRL ITGDFKQGHS IVVSSLKIFY KTVSFIMADE QLKRISKVQA KPAVEHRVAE LMVYREADWV KKTGDKLTIL IKKIIECVSV HPHWKVRLEL VELVEDLLLK CSQSLVECAG PLLKALVGLV NDESPEIQAQ CNKVLRHFAD QKVVVGNKAL ADILSESLHS LATSLPRLMN SQDDQGKFST LSLLLGYLKL LGPKINFVLN SVAHLQRLSK ALIQVLELDV ADIKIVEERR WNSDDLNASP KTSATQPWNR IQRRYFRFFT DERIFMLLRQ VCQLLGYYGN LYLLVDHFME LYHQSVVYRK QAAMILNELV TGAAGLEVED LHEKHIKTNP EELREIVTSI LEEYTSQENW YLVTCLETEE MGEELMMEHP GLQAITSGEH TCQVTSFLAF SKPSPTICSM NSNIWQICIQ LEGIGQFAYA LGKDFCLLLM SALYPVLEKA GDQTLLISQV ATSTMMDVCR ACGYDSLQHL INQNSDYLVN GISLNLRHLA LHPHTPKVLE VMLRNSDANL LPLVADVVQD VLATLDQFYD KRAASFVSVL HALMAALAQW FPDTGNLGHL QEQSLGEEGS HLNQRPAALE KSTTTAEDIE QFLLNYLKEK DVADGNVSDF DNEEEEQSVP PKVDENDTRP DVEPPLPLQI QIAMDVMERC IHLLSDKNLQ IRLKVLDVLD LCVVVLQSHK NQLLPLAHQA WPSLVHRLTR DAPLAVLRAF KVLRTLGSKC GDFLRSRFCK DVLPKLAGSL VTQAPISARA GPVYSHTLAF KLQLAVLQGL GPLCERLDLG EGDLNKVADA CLIYLSVKQP VKLQEAARSV FLHLMKVDPD STWFLLNELY CPVQFTPPHP SLHPVQLHGA SGQQNPYTTN VLQLLKELQ
Explore TELO2-interacting protein 1 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets